Summary
Global Markets Direct’s, ‘Cough - Pipeline Review, H1 2016’, provides an overview of the Cough pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cough
- The report reviews pipeline therapeutics for Cough by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cough therapeutics and enlists all their major and minor projects
- The report assesses Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cough
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cough
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Afferent Pharmaceuticals, Inc.
Alitair Pharmaceuticals, Inc.
Ario Pharma Ltd
AstraZeneca Plc
AUS Bio Limited
Conrig Pharma ApS
Daewoong Pharmaceutical Co., Ltd.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
GW Pharmaceuticals Plc
Hyundai Pharmaceutical Co., Ltd.
Johnson & Johnson
NeRRe Therapeutics Ltd
Orbis Biosciences, Inc.
Patara Pharma, Inc.
Vernalis Plc
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Cough Overview 9
Therapeutics Development 10
Pipeline Products for Cough - Overview 10
Pipeline Products for Cough - Comparative Analysis 11
Cough - Therapeutics under Development by Companies 12
Cough - Therapeutics under Investigation by Universities/Institutes 13
Cough - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Cough - Products under Development by Companies 18
Cough - Products under Investigation by Universities/Institutes 19
Cough - Companies Involved in Therapeutics Development 20
Afferent Pharmaceuticals, Inc. 20
Alitair Pharmaceuticals, Inc. 21
Ario Pharma Ltd 22
AstraZeneca Plc 23
AUS Bio Limited 24
Conrig Pharma ApS 25
Daewoong Pharmaceutical Co., Ltd. 26
GlaxoSmithKline Plc 27
Glenmark Pharmaceuticals Ltd. 28
GW Pharmaceuticals Plc 29
Hyundai Pharmaceutical Co., Ltd. 30
Johnson & Johnson 31
NeRRe Therapeutics Ltd 32
Orbis Biosciences, Inc. 33
Patara Pharma, Inc. 34
Vernalis Plc 35
Cough - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 45
AF-219 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
benzonatate polacrilex - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CCP-05 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CCP-06 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CCP-07 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CCP-08 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
codeine + guaifenesin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
cromolyn sodium - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DWJ-1340 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
GRC-17536 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
GSK-2339345 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
guaifenesin + hydrocodone - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
guaifenesin ER - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
JNJ-39729209 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
lesogaberan - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
levodropropizine CR - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MD-990 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
NEO-5024 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
NEO-5937 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
orvepitant maleate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
S-1226 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ST-015 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
XEND-0501 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Cough - Recent Pipeline Updates 74
Cough - Dormant Projects 80
Cough - Discontinued Products 83
Cough - Product Development Milestones 84
Featured News & Press Releases 84
Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study 84
Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing 84
Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial 84
Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine 85
Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing 86
Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 86
Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 87
Apr 29, 2014: Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept 88
Dec 11, 2013: Ario Pharma to Develop Novel Therapeutics for Respiratory Indications 88
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 89
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92
List of Tables
Number of Products under Development for Cough, H1 2016 10
Number of Products under Development for Cough - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Comparative Analysis by Unknown Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Cough - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016 20
Cough - Pipeline by Alitair Pharmaceuticals, Inc., H1 2016 21
Cough - Pipeline by Ario Pharma Ltd, H1 2016 22
Cough - Pipeline by AstraZeneca Plc, H1 2016 23
Cough - Pipeline by AUS Bio Limited, H1 2016 24
Cough - Pipeline by Conrig Pharma ApS, H1 2016 25
Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 26
Cough - Pipeline by GlaxoSmithKline Plc, H1 2016 27
Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 28
Cough - Pipeline by GW Pharmaceuticals Plc, H1 2016 29
Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 30
Cough - Pipeline by Johnson & Johnson, H1 2016 31
Cough - Pipeline by NeRRe Therapeutics Ltd, H1 2016 32
Cough - Pipeline by Orbis Biosciences, Inc., H1 2016 33
Cough - Pipeline by Patara Pharma, Inc., H1 2016 34
Cough - Pipeline by Vernalis Plc, H1 2016 35
Assessment by Monotherapy Products, H1 2016 36
Assessment by Combination Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Mechanism of Action, H1 2016 41
Number of Products by Stage and Route of Administration, H1 2016 43
Number of Products by Stage and Molecule Type, H1 2016 44
Cough Therapeutics - Recent Pipeline Updates, H1 2016 74
Cough - Dormant Projects, H1 2016 80
Cough - Dormant Projects (Contd..1), H1 2016 81
Cough - Dormant Projects (Contd..2), H1 2016 82
Cough - Discontinued Products, H1 2016 83
List of Figures
Number of Products under Development for Cough, H1 2016 10
Number of Products under Development for Cough - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 16
Assessment by Monotherapy Products, H1 2016 36
Number of Products by Top 10 Targets, H1 2016 38
Number of Products by Stage and Top 10 Targets, H1 2016 38
Number of Products by Top 10 Mechanism of Actions, H1 2016 40
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 40
Number of Products by Routes of Administration, H1 2016 42
Number of Products by Stage and Routes of Administration, H1 2016 42
Number of Products by Stage and Molecule Types, H1 2016 44
